CD8A and neoplasm: In a PC mouse model, the simultaneous administration of IL-15, anti-CTLA-4, and anti-PDL-1 was associated with increased number of CD8+ T cells, T cell lytic activity, and IFN-γ release, decreased tumor growth, and improved mice survival (compared to IL-15 alone) [152].